𝔖 Bobbio Scriptorium

✦ LIBER ✦

3004 ORAL Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) in the first-line treatment of metastastic colorectal cancer (mCRC): a large-scale phase II study, OPUS

✍ Scribed by C. Bokemeyer; E. Staroslawska; A. Makhson; I. Bondarenko; J.T. Hartmann; Y. Shelygin; O. Kolesnik; C. Volovat; A. Zubel; P. Koralewski

Book ID: 118625774
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 60 KB
Volume: 5
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(07)70932-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

642 POSTER Cetuximab plus oxaliplatin/5-

642 POSTER Cetuximab plus oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) for the epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer (mCRC) in the first-line setting: a phase II study

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 268 KB

636 POSTER Initial safety findings from

636 POSTER Initial safety findings from a phase III study of capecitabine (X) plus oxaliplatin (XELOX) vs. infusional 5-FU/LV plus oxaliplatin (FOLFOX-6) in first-line treatment of patients (pts) with metastatic colorectal cancer (MCRC)

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 258 KB

6096 POSTER FOLFOXIRI (Irinotecan, Oxali

6096 POSTER FOLFOXIRI (Irinotecan, Oxaliplatin, and Infusional 5FU/LV) in Combination With Panitumumab (P) in the First-line Treatment of Metastatic Colorectal Cancer (mCRC) Patients (pts) Selected for KRAS, BRAF, NRas and HRas Mutational Status – a Phase II Study by the G.O.N.O. Group

✍ Fornaro, L.; Loupakis, F.; Lonardi, S.; Masi, G.; Salvatore, L.; Cremolini, C.; 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 49 KB